State of New York and Gilead Sciences

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/1/2021 Talkpace's experiment, Illumina's headache, & remembering John Martin STAT ... New York University antitrust expert Eleanor Fox calls in to discuss the case of Illumina, the genome sequencing giant whose grand plans keeping running afoul of the Federal Trade Commission. Finally, we embark on a lightning round, covering the latest Covid-19 vaccine news, biotech‚Aos biggest events over the next three months, and the death of a pioneering Gilead Sciences executive.For more on what we cover, here‚Aos ...
3/7/2021 Oxford Covid-19 Vaccine Startup in Conflict with University Ahead of Planned IPO - WSJ The Wall Street Journal ... New York as early as this year, according to people close to the plans and marketing documents reviewed by The Wall Street Journal.Investors are aiming for an IPO valuation of around $700 million, with expectations that Vaccitech could be a $1 billion company by year-end. Big investors such as pharmaceutical giant Gilead Sciences Inc. and Lilly Asia Ventures, a venture-capital arm spun off from drugmaker Eli Lilly ...
2/26/2021 Bank of New York Mellon Corp Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) Bank of New York Mellon Corp Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) Posted by Floyd Graber on Feb 26th, 2021Bank of New York Mellon Corp lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,806,532 shares of the biopharmaceutical company‚Aos stock after selling 2,625,006 shares during ...
2/20/2021 New York State Common Retirement Fund Has $150.81 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsNew York State Common Retirement Fund cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,588,567 shares of the biopharmaceutical company‚Aos stock after selling 162,447 shares during the quarter. New York State Common ...
1/27/2021 Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead ‚Äî Boosted by Taxpayers Kaiser Health News ... Auhighly significant‚Au news about a drug called remdesivir. /p p That was surprising because the antiviral drug, owned by Gilead Sciences and developed with investment from the federal government, had languished for years with ... the Centers for Disease Control and Prevention, co-authored a New York Times opinion piece a href="https://www.nytimes.com/2020/07/28/opinion/remdesivir-shortage-coronavirus.html" suggesting /a that HHS could buy the drug from another company ...
1/1/2021 Immunovant (NASDAQ:IMVT) & Gilead Sciences (NASDAQ:GILD) Critical Review Gilead Sciences beats Immunovant on 9 of the 12 factors compared between the two stocks.About ImmunovantImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops ... of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.About Gilead SciencesGilead Sciences, Inc., a research-based biopharmaceutical company, discovers ...
11/2/2020 Vaccine Development Holdups Reinforce the Need for Interim Solutions PR Newswire NEW YORK , Nov. 2, 2020 /PRNewswire/ -- The number of new cases continues to rise, and new restrictions are being implemented. As the pandemic remains a major threat, the development of a new vaccine is imperative ... stroke. Todos Medical Ltd. (OTC: TOMDF), Pfizer Inc. (NYSE: PFE ), Gilead Sciences, Inc. (NASDAQ: GILD ), Vaxart, Inc. (NASDAQ: VXRT ), Moderna, Inc. (NASDAQ: MRNA )"While it's unfortunate, I don't find it surprising that the timeline is ...
10/22/2020 Anthony Welters Joins Gilead Sciences’ Board of Directors BioSpace ... New York University School of Law, as well as Vice Chairman of the Board of New York University and a Trustee of NYU Langone Medical Center.“We are very pleased to welcome Tony Welters to our Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Tony understands the urgency of delivering exceptional healthcare to communities most in need. His extensive experience in the health insurance ...
10/2/2020 Corona rules: What was crucial for Yom Kippur is just as crucial for Sukkot - Opeds - Israel National News Oct. 1 (UPI) -- Gilead Sciences will resume control of the distribution of remdesivir as a COVID-19 treatment to U.S. hospitals, the Food and Drug Administration announced Thursday.Gilead manufactures remdesivir under the name Veklury ... according to Gilead Sciences.COVID-19 pandemic alters life in New York City Mannequins with face masks and designer clothing fill a window at a Diane Von Furstenberg store in New York City on September ...
9/17/2020 Coronavirus tracker: Pfizer unveils trial protocol for vaccine; Treasurers ask Gilead to lower remdesivir price | FiercePharma FiercePharma ... New York drugmaker released a 137-page document outlining all of the details of the trial, which has already enrolled about 29,000 people. A group of 11 state treasurers from both political parties asked Gilead Sciences to reconsider its pricing on antiviral remdesivir. The treasurers say taxpayers "have already paid the price" and "deserve an affordable treatment when loved ones" face severe COVID-19 cases. Gilead's treatment carries a list ...
9/15/2020 Our Ultimate Stock Pickers' Top 10 Dividend-Yielding Stocks | Morningstar Morningstar ... Gilead Sciences ( GILD ) , Novartis ( NVS ) , and Bank of New York Mellon ( BK ) , and narrow-moat rated CVS Health ( CVS ) and Cisco Systems ( CSCO ) were part of the old list, as well. Wide-moat rated Gilead Sciences and Bank of New York Mellon, and narrow-moat rated Cisco Systems and CVS Health moved up the list, and wide-moat rated Novartis moved down the list. The top 10 widely held dividend ...
8/10/2020 New Testing Methods Help Ease Diagnostic Burdens in Healthcare PR Newswire NEW YORK , Aug. 10, As healthcare systems come under severe pressure from the pandemic, significant changes to their infrastructure are required. In particular, technological changes to transform service delivery and scale up the utilization of ... VIR ), Moderna, Inc. (NASDAQ: MRNA ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Gilead Sciences, Inc. (NASDAQ: GILD ) New York is a good example of how excessive testing can influence policy. In recent days, Governor Cuomo talked about ...
8/9/2020 Big Pharma plays CMO as Pfizer signs on to produce Covid-19 drug remdesivir for Gilead - MedCity News MedCity News A large U.S. drugmaker is partnering with Gilead Sciences to manufacture the latter company’s antiviral drug for treating Covid-19. New York-based Pfizer said Friday that it had made a multi-year agreement with Foster City, California-based Gilead to manufacture remdesivir, the antiviral drug that received an emergency use authorization from the Food and Drug Administration for patients hospitalized with Covid-19 in May. Pfizer will produce the ...
7/31/2020 Coronavirus tracker: Sanofi, GSK win Warp Speed blessing, $2.1B; Pfizer, BioNTech commit 120M vaccines to Japan | FiercePharma FiercePharma The National Institutes of Health cut the tape on a phase 3 trial pitting a combination of Gilead Sciences' remdesivir and Merck KGaA's multiple sclerosis med Rebif against remdesivir alone. Plus, the German drugmaker is ... in the nose, throat and lungs as symptomatic patients, the New York Times reports . Though medical experts thought as much, it's the first study to confirm the fact. "[I]t does confirm what we’ve suspected ...
7/21/2020 COVID-19 Vaccine And Therapeutics Pipeline Analysis 2020 Globe Newswire Major players in the COVID19 vaccine and therapeutics pipeline analysis market are CanSino Biologics, Moderna, Inovio Pharmaceuticals, Regeneron, Gilead Sciences, GlaxoSmithKline, Medicago Inc. , Sanofi, University of Oxford, and Altimmune. July 21, 2020 09:39 ET Source: ReportLinker New York, Reportlinker.com announces the release of the report "COVID-19 Vaccine And Therapeutics Pipeline Analysis 2020" - https://www.reportlinker.com/p05933754/?utm_source=GNW The COVID19 vaccine and therapeutics pipeline analysis market covered in this ...
7/8/2020 ViiV's twice-monthly injected PrEP drug superior in HIV prevention to Gilead daily pill, analysis shows - MedCity News MedCity News An injected drug given every two months has shown superiority to an approved oral drug in preventing HIV infection, according to newly presented data. ViiV Healthcare – controlled by London-based GlaxoSmithKline, New York-based Pfizer and Osaka, Japan-based Shionogi – said Tuesday that in the final data analysis of the 4,600-participant Phase IIb/III HPTN 083 study comparing the injected drug cabotegravir against Gilead Sciences’ oral Truvada (emtricitabine, tenofovir ...
7/7/2020 BARDA, DoD give Regeneron $450M contract for Covid-19 antiviral drug MedCity News ... drug candidate for Covid-19 into late-stage clinical testing has a new, lucrative contract from the federal government. Tarrytown, New York-based Regeneron Pharmaceuticals said Tuesday that it had received a contract worth $450 ... secondary endpoints. Other firms developing antivirals include Vir Biotechnology, while Gilead Sciences has secured an EUA for its drug, remdesivir. Photo: Feodora Chiosea, Getty Images ...
7/6/2020 Regeneron starts late-stage trials of antiviral antibody cocktail in Covid-19 - MedCity News MedCity News ... failure of its study of a drug it already markets for treating symptoms associated with Covid-19-related inflammation. Tarrytown, New York-based Regeneron Pharmaceuticals said Monday that it and the National Institute of Allergy ... its primary or key secondary endpoints. Unlike REGN-COV2 and Gilead Sciences’ remdesivir, Kevzara was among a large number of drugs being explored in Covid-19 patients as a treatment for the immune system overreaction ...
6/30/2020 U.S. Cases Rise 1.2%; Worst Yet to Come, WHO Says: Virus Update MSN ... New York City said it’s considering the same move as other U.S. states experience a surge in Covid-19 cases after reopening restaurants and bars. One of those states, Florida, reported a jump in its double-digit infection rate. Gilead Sciences Inc. said it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir, or about $2,340 for a typical five-day ...
6/29/2020 Contact-tracing 'not going well,' Fauci says; remdesivir gets price tag — 4 COVID-19 updates Becker's Hospital Review The global COVID-19 case count surpassed 10 million June 28, reports The New York Times. There have been more than 500,000 confirmed deaths, with the U.S. accounting for more than a quarter of them ... the U.S. with private insurance , according to a pricing plan Gilead Sciences shared June 29. The drugmaker said it will begin to charge developed countries $390 per vial for the COVID-19 treatment in July ...
6/25/2020 Biotechs are booming -- but it's not all about Covid-19 - CNN CNN New York (CNN Business) Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences ( GILD ) , Moderna ( MRNA ) and Novavax ( NVAX ) . But a biotech boom is also taking place in the initial public offering market. Several recent biotech IPOs have soared since their debuts -- even though not a single one of them is ...